Neda Rasouli
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Insulin Resistance | 38 | 2024 | 1165 | 4.510 |
Why?
| Diabetes Mellitus, Type 2 | 38 | 2025 | 2441 | 3.730 |
Why?
| Metformin | 19 | 2025 | 315 | 2.970 |
Why?
| Thiazolidinediones | 20 | 2014 | 137 | 2.410 |
Why?
| Prediabetic State | 10 | 2024 | 246 | 2.360 |
Why?
| Adipose Tissue | 24 | 2016 | 592 | 2.170 |
Why?
| Insulin-Secreting Cells | 8 | 2025 | 367 | 2.040 |
Why?
| Hypoglycemic Agents | 32 | 2025 | 1220 | 2.000 |
Why?
| Sulfonylurea Compounds | 6 | 2025 | 46 | 1.460 |
Why?
| Blood Glucose | 26 | 2025 | 2097 | 1.350 |
Why?
| Vitamin D Deficiency | 2 | 2022 | 176 | 1.330 |
Why?
| Obesity | 24 | 2019 | 2883 | 1.280 |
Why?
| Cholecalciferol | 4 | 2022 | 56 | 1.220 |
Why?
| Cholesterol, HDL | 2 | 2018 | 205 | 1.010 |
Why?
| Insulin | 22 | 2024 | 2326 | 1.000 |
Why?
| Triglycerides | 3 | 2018 | 527 | 0.920 |
Why?
| Fenofibrate | 2 | 2016 | 31 | 0.910 |
Why?
| Glucose Tolerance Test | 15 | 2025 | 356 | 0.880 |
Why?
| Insulin Glargine | 9 | 2025 | 81 | 0.830 |
Why?
| Muscle, Skeletal | 11 | 2016 | 1614 | 0.790 |
Why?
| Metabolic Syndrome | 3 | 2018 | 339 | 0.730 |
Why?
| Receptors, Ghrelin | 1 | 2020 | 8 | 0.700 |
Why?
| Gastroparesis | 1 | 2020 | 9 | 0.700 |
Why?
| PPAR gamma | 8 | 2014 | 183 | 0.690 |
Why?
| Lipid Metabolism | 5 | 2016 | 497 | 0.670 |
Why?
| Diabetic Neuropathies | 1 | 2020 | 96 | 0.640 |
Why?
| Vitamin D | 9 | 2024 | 384 | 0.640 |
Why?
| Glucose | 9 | 2024 | 1003 | 0.640 |
Why?
| Adipokines | 2 | 2010 | 47 | 0.630 |
Why?
| Diabetes Mellitus | 6 | 2020 | 1001 | 0.610 |
Why?
| Hypoxia | 2 | 2016 | 1084 | 0.610 |
Why?
| Middle Aged | 50 | 2025 | 31154 | 0.600 |
Why?
| Subcutaneous Fat | 5 | 2014 | 74 | 0.600 |
Why?
| Adipocytes | 11 | 2014 | 205 | 0.580 |
Why?
| Dietary Supplements | 7 | 2022 | 534 | 0.530 |
Why?
| Hyperglycemia | 5 | 2016 | 328 | 0.530 |
Why?
| Humans | 84 | 2025 | 129650 | 0.510 |
Why?
| Vitamins | 6 | 2024 | 174 | 0.500 |
Why?
| Remote Consultation | 1 | 2016 | 47 | 0.500 |
Why?
| Sitagliptin Phosphate | 6 | 2025 | 31 | 0.480 |
Why?
| Liraglutide | 6 | 2025 | 29 | 0.480 |
Why?
| Fibrosis | 3 | 2023 | 520 | 0.480 |
Why?
| Fatty Acids | 2 | 2016 | 427 | 0.470 |
Why?
| Macrophages | 10 | 2014 | 1480 | 0.460 |
Why?
| Inflammation | 12 | 2016 | 2736 | 0.450 |
Why?
| Adult | 43 | 2022 | 35576 | 0.430 |
Why?
| Aged | 28 | 2025 | 22103 | 0.430 |
Why?
| C-Peptide | 3 | 2024 | 163 | 0.410 |
Why?
| Female | 47 | 2025 | 68776 | 0.410 |
Why?
| Male | 46 | 2025 | 63681 | 0.400 |
Why?
| Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 16 | 0.400 |
Why?
| SUMO-1 Protein | 1 | 2012 | 20 | 0.390 |
Why?
| Glucose Intolerance | 6 | 2010 | 142 | 0.370 |
Why?
| Lipids | 2 | 2020 | 625 | 0.360 |
Why?
| Patient Admission | 1 | 2012 | 182 | 0.350 |
Why?
| Cohort Studies | 7 | 2020 | 5420 | 0.350 |
Why?
| Histone Deacetylases | 1 | 2012 | 212 | 0.340 |
Why?
| Receptors, Scavenger | 1 | 2009 | 21 | 0.320 |
Why?
| Inpatients | 2 | 2013 | 467 | 0.320 |
Why?
| Gene Expression Regulation | 6 | 2015 | 2548 | 0.310 |
Why?
| Peripheral Arterial Disease | 2 | 2025 | 457 | 0.290 |
Why?
| Gene Expression | 7 | 2010 | 1472 | 0.290 |
Why?
| Metabolic Diseases | 1 | 2008 | 104 | 0.280 |
Why?
| Body Mass Index | 11 | 2021 | 2273 | 0.280 |
Why?
| Intermittent Claudication | 2 | 2025 | 118 | 0.270 |
Why?
| Adipose Tissue, White | 2 | 2019 | 37 | 0.270 |
Why?
| Choristoma | 1 | 2007 | 21 | 0.270 |
Why?
| Dietary Fats | 1 | 2008 | 301 | 0.260 |
Why?
| Muscles | 3 | 2012 | 322 | 0.250 |
Why?
| Incretins | 1 | 2025 | 18 | 0.230 |
Why?
| Glucagon-Like Peptides | 1 | 2025 | 50 | 0.220 |
Why?
| Gene Expression Regulation, Enzymologic | 3 | 2013 | 287 | 0.220 |
Why?
| Young Adult | 11 | 2016 | 12426 | 0.220 |
Why?
| Treatment Outcome | 9 | 2025 | 10230 | 0.220 |
Why?
| RNA, Messenger | 11 | 2015 | 2708 | 0.210 |
Why?
| Double-Blind Method | 6 | 2025 | 1876 | 0.210 |
Why?
| Adiponectin | 4 | 2009 | 235 | 0.200 |
Why?
| Cystic Fibrosis | 1 | 2012 | 1053 | 0.200 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2022 | 45 | 0.200 |
Why?
| Islets of Langerhans | 2 | 2005 | 791 | 0.190 |
Why?
| Insulin, Long-Acting | 2 | 2012 | 62 | 0.190 |
Why?
| Follow-Up Studies | 2 | 2022 | 4897 | 0.180 |
Why?
| Ligands | 3 | 2012 | 622 | 0.180 |
Why?
| Metoclopramide | 1 | 2020 | 19 | 0.180 |
Why?
| Gastric Emptying | 1 | 2020 | 40 | 0.170 |
Why?
| Cross-Sectional Studies | 5 | 2024 | 5066 | 0.170 |
Why?
| Glucosides | 1 | 2020 | 38 | 0.170 |
Why?
| Walking | 1 | 2025 | 501 | 0.170 |
Why?
| Enteral Nutrition | 2 | 2012 | 188 | 0.170 |
Why?
| Quantitative Trait Loci | 2 | 2012 | 355 | 0.170 |
Why?
| China | 1 | 2020 | 191 | 0.170 |
Why?
| Benzhydryl Compounds | 1 | 2020 | 66 | 0.170 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 261 | 0.160 |
Why?
| Cardiology | 1 | 2022 | 261 | 0.160 |
Why?
| Renal Insufficiency | 1 | 2021 | 149 | 0.160 |
Why?
| Atherosclerosis | 2 | 2018 | 402 | 0.160 |
Why?
| Coculture Techniques | 5 | 2011 | 226 | 0.160 |
Why?
| Insulin, Short-Acting | 1 | 2018 | 6 | 0.160 |
Why?
| Linagliptin | 1 | 2018 | 5 | 0.160 |
Why?
| Cardiovascular Diseases | 3 | 2022 | 2004 | 0.150 |
Why?
| Adipose Tissue, Brown | 1 | 2019 | 51 | 0.150 |
Why?
| Gene Expression Profiling | 4 | 2015 | 1706 | 0.150 |
Why?
| Hyperoxia | 1 | 2019 | 90 | 0.150 |
Why?
| Incidence | 2 | 2022 | 2644 | 0.140 |
Why?
| Glomerular Filtration Rate | 1 | 2021 | 711 | 0.140 |
Why?
| Cells, Cultured | 6 | 2016 | 4083 | 0.140 |
Why?
| Perioperative Care | 1 | 2018 | 152 | 0.140 |
Why?
| Overweight | 1 | 2022 | 531 | 0.140 |
Why?
| Quality of Life | 3 | 2025 | 2704 | 0.130 |
Why?
| Surgical Procedures, Operative | 1 | 2018 | 244 | 0.130 |
Why?
| Abdominal Fat | 2 | 2006 | 40 | 0.130 |
Why?
| Endoplasmic Reticulum | 2 | 2008 | 261 | 0.120 |
Why?
| Medical Staff, Hospital | 1 | 2016 | 78 | 0.120 |
Why?
| Body Weight | 1 | 2020 | 940 | 0.120 |
Why?
| Endocrinology | 1 | 2016 | 75 | 0.120 |
Why?
| Arginine | 2 | 2007 | 265 | 0.120 |
Why?
| Drug Therapy, Combination | 3 | 2024 | 1040 | 0.120 |
Why?
| Cell Line | 6 | 2010 | 2781 | 0.110 |
Why?
| Thermogenesis | 1 | 2014 | 44 | 0.110 |
Why?
| Scavenger Receptors, Class E | 2 | 2015 | 2 | 0.110 |
Why?
| Fish Oils | 1 | 2014 | 26 | 0.110 |
Why?
| Hospitalization | 4 | 2018 | 2070 | 0.110 |
Why?
| Oxidation-Reduction | 2 | 2016 | 1033 | 0.110 |
Why?
| Adolescent | 7 | 2016 | 20393 | 0.110 |
Why?
| Risk Factors | 7 | 2025 | 9765 | 0.110 |
Why?
| Area Under Curve | 1 | 2015 | 304 | 0.110 |
Why?
| Palmitic Acid | 3 | 2011 | 40 | 0.110 |
Why?
| Glucagon-Like Peptide 1 | 2 | 2025 | 112 | 0.110 |
Why?
| Adiposity | 2 | 2010 | 504 | 0.110 |
Why?
| Acetyl-CoA Carboxylase | 1 | 2013 | 33 | 0.100 |
Why?
| ROC Curve | 1 | 2015 | 503 | 0.100 |
Why?
| Medically Uninsured | 1 | 2014 | 127 | 0.100 |
Why?
| Muscle Fibers, Skeletal | 2 | 2011 | 187 | 0.100 |
Why?
| Transcriptional Activation | 1 | 2014 | 366 | 0.100 |
Why?
| Biopsy | 3 | 2012 | 1097 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2012 | 587 | 0.100 |
Why?
| Cardiomyopathies | 2 | 2007 | 340 | 0.100 |
Why?
| PPAR alpha | 1 | 2012 | 58 | 0.100 |
Why?
| CD36 Antigens | 2 | 2009 | 36 | 0.100 |
Why?
| Seasons | 1 | 2014 | 502 | 0.100 |
Why?
| Biphasic Insulins | 1 | 2011 | 3 | 0.100 |
Why?
| Patient Preference | 1 | 2014 | 185 | 0.100 |
Why?
| Cytokines | 4 | 2010 | 2017 | 0.100 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2023 | 1368 | 0.100 |
Why?
| Insulin Infusion Systems | 2 | 2012 | 363 | 0.090 |
Why?
| Insulin Lispro | 1 | 2011 | 39 | 0.090 |
Why?
| Retrospective Studies | 5 | 2016 | 14518 | 0.090 |
Why?
| Antigens, Differentiation, Myelomonocytic | 3 | 2007 | 60 | 0.090 |
Why?
| Temperature | 1 | 2014 | 636 | 0.090 |
Why?
| Hypolipidemic Agents | 2 | 2018 | 92 | 0.090 |
Why?
| Continuity of Patient Care | 1 | 2014 | 275 | 0.090 |
Why?
| Patient Care Team | 1 | 2016 | 605 | 0.090 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2011 | 161 | 0.090 |
Why?
| Docosahexaenoic Acids | 1 | 2011 | 83 | 0.090 |
Why?
| Molecular Weight | 2 | 2008 | 332 | 0.090 |
Why?
| Collagen Type VI | 1 | 2010 | 6 | 0.090 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 15 | 0.090 |
Why?
| Lipase | 1 | 2010 | 66 | 0.090 |
Why?
| Comparative Effectiveness Research | 2 | 2022 | 149 | 0.080 |
Why?
| Prognosis | 1 | 2018 | 3794 | 0.080 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2013 | 2073 | 0.080 |
Why?
| Body Composition | 3 | 2011 | 649 | 0.080 |
Why?
| Adipogenesis | 1 | 2010 | 50 | 0.080 |
Why?
| Lipogenesis | 1 | 2010 | 59 | 0.080 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2010 | 119 | 0.080 |
Why?
| Injections, Subcutaneous | 2 | 2025 | 147 | 0.080 |
Why?
| Scavenger Receptors, Class A | 1 | 2009 | 11 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 958 | 0.080 |
Why?
| Medicaid | 1 | 2014 | 433 | 0.080 |
Why?
| Bicycling | 1 | 2010 | 116 | 0.080 |
Why?
| Logistic Models | 1 | 2015 | 1988 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2019 | 4063 | 0.080 |
Why?
| Predictive Value of Tests | 1 | 2015 | 1952 | 0.080 |
Why?
| Diabetic Nephropathies | 1 | 2013 | 284 | 0.080 |
Why?
| Myoblasts, Skeletal | 1 | 2009 | 12 | 0.080 |
Why?
| MicroRNAs | 1 | 2015 | 678 | 0.080 |
Why?
| Antigens, CD | 3 | 2007 | 489 | 0.080 |
Why?
| Heart Failure | 1 | 2022 | 2150 | 0.080 |
Why?
| Myositis | 1 | 2009 | 51 | 0.080 |
Why?
| Chemokine CCL2 | 2 | 2007 | 118 | 0.080 |
Why?
| Biomarkers | 4 | 2025 | 3973 | 0.080 |
Why?
| Fatty Acids, Nonesterified | 1 | 2009 | 160 | 0.070 |
Why?
| Stress, Physiological | 2 | 2008 | 413 | 0.070 |
Why?
| Stearoyl-CoA Desaturase | 1 | 2008 | 65 | 0.070 |
Why?
| Infant | 2 | 2020 | 9024 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 2012 | 0.070 |
Why?
| Thrombospondin 1 | 1 | 2007 | 26 | 0.070 |
Why?
| Anti-Inflammatory Agents | 1 | 2011 | 480 | 0.070 |
Why?
| Retinol-Binding Proteins | 1 | 2007 | 14 | 0.070 |
Why?
| TCF Transcription Factors | 1 | 2007 | 16 | 0.070 |
Why?
| Extracellular Matrix | 1 | 2011 | 504 | 0.070 |
Why?
| Administration, Oral | 2 | 2020 | 786 | 0.070 |
Why?
| Adipocytes, White | 2 | 2019 | 17 | 0.070 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 15 | 0.070 |
Why?
| Down-Regulation | 1 | 2009 | 636 | 0.070 |
Why?
| Diacylglycerol O-Acyltransferase | 1 | 2006 | 3 | 0.070 |
Why?
| Animals | 10 | 2019 | 35361 | 0.070 |
Why?
| Fatty Acid Synthases | 1 | 2006 | 24 | 0.070 |
Why?
| Liver | 3 | 2013 | 1839 | 0.060 |
Why?
| Transcriptome | 1 | 2012 | 887 | 0.060 |
Why?
| Lipoprotein Lipase | 1 | 2006 | 59 | 0.060 |
Why?
| Child, Preschool | 1 | 2020 | 10517 | 0.060 |
Why?
| Cell Differentiation | 2 | 2011 | 1902 | 0.060 |
Why?
| Resistin | 1 | 2005 | 11 | 0.060 |
Why?
| Niacin | 1 | 2005 | 19 | 0.060 |
Why?
| Genome-Wide Association Study | 1 | 2012 | 1333 | 0.060 |
Why?
| Quality Improvement | 1 | 2014 | 1103 | 0.060 |
Why?
| Ankle Brachial Index | 1 | 2025 | 36 | 0.060 |
Why?
| Fructosamine | 1 | 2004 | 15 | 0.060 |
Why?
| Veterans | 1 | 2016 | 1398 | 0.060 |
Why?
| Walk Test | 1 | 2025 | 70 | 0.060 |
Why?
| Models, Biological | 2 | 2008 | 1722 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2013 | 2282 | 0.060 |
Why?
| Apolipoproteins E | 1 | 2004 | 77 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 315 | 0.060 |
Why?
| Insulin, Regular, Human | 1 | 2024 | 43 | 0.060 |
Why?
| Polymorphism, Genetic | 1 | 2007 | 640 | 0.060 |
Why?
| Leptin | 1 | 2005 | 219 | 0.060 |
Why?
| Diabetes Complications | 1 | 2006 | 224 | 0.060 |
Why?
| Phenotype | 1 | 2012 | 3076 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 442 | 0.050 |
Why?
| Diabetes Mellitus, Type 1 | 3 | 2014 | 3628 | 0.050 |
Why?
| Elastin | 2 | 2014 | 77 | 0.050 |
Why?
| Anti-Obesity Agents | 2 | 2018 | 53 | 0.050 |
Why?
| Obesity, Morbid | 1 | 2006 | 240 | 0.050 |
Why?
| Exercise Tolerance | 1 | 2025 | 273 | 0.050 |
Why?
| Diabetic Ketoacidosis | 1 | 2004 | 197 | 0.050 |
Why?
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 92 | 0.050 |
Why?
| Arteriosclerosis | 1 | 2002 | 88 | 0.050 |
Why?
| Nuclear Proteins | 1 | 2006 | 663 | 0.050 |
Why?
| Apoptosis | 2 | 2011 | 2503 | 0.050 |
Why?
| Child | 1 | 2020 | 20883 | 0.040 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.040 |
Why?
| Hypoglycemia | 2 | 2018 | 427 | 0.040 |
Why?
| Liver Cirrhosis | 1 | 2023 | 280 | 0.040 |
Why?
| Recovery of Function | 1 | 2025 | 642 | 0.040 |
Why?
| American Heart Association | 1 | 2022 | 296 | 0.040 |
Why?
| Coronary Artery Disease | 1 | 2007 | 679 | 0.040 |
Why?
| Albuminuria | 1 | 2021 | 183 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 286 | 0.040 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 198 | 0.040 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 217 | 0.040 |
Why?
| Calibration | 1 | 2020 | 140 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2020 | 193 | 0.040 |
Why?
| Creatinine | 1 | 2021 | 491 | 0.040 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1198 | 0.040 |
Why?
| Consensus | 1 | 2022 | 616 | 0.040 |
Why?
| Adipocytes, Brown | 1 | 2019 | 7 | 0.040 |
Why?
| Oxidative Stress | 1 | 2006 | 1269 | 0.040 |
Why?
| Streptozocin | 1 | 2019 | 20 | 0.040 |
Why?
| Health Status Indicators | 1 | 2020 | 167 | 0.040 |
Why?
| Mice | 7 | 2013 | 16937 | 0.040 |
Why?
| Carbohydrate Metabolism | 1 | 2019 | 62 | 0.040 |
Why?
| Gynecologic Surgical Procedures | 1 | 2018 | 56 | 0.040 |
Why?
| Transcription Factors | 2 | 2008 | 1651 | 0.040 |
Why?
| Fasting | 1 | 2020 | 267 | 0.040 |
Why?
| Treatment Failure | 1 | 2019 | 340 | 0.040 |
Why?
| Digestive System Surgical Procedures | 1 | 2018 | 96 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2019 | 648 | 0.040 |
Why?
| Urologic Surgical Procedures | 1 | 2018 | 107 | 0.040 |
Why?
| Rats, Wistar | 1 | 2019 | 441 | 0.040 |
Why?
| Diet, High-Fat | 1 | 2019 | 239 | 0.030 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2019 | 182 | 0.030 |
Why?
| Transfection | 2 | 2010 | 911 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 857 | 0.030 |
Why?
| Blotting, Western | 2 | 2010 | 1205 | 0.030 |
Why?
| Reference Values | 2 | 2008 | 793 | 0.030 |
Why?
| G(M2) Activator Protein | 1 | 2015 | 1 | 0.030 |
Why?
| Orthopedic Procedures | 1 | 2018 | 210 | 0.030 |
Why?
| Myosin Type V | 1 | 2015 | 9 | 0.030 |
Why?
| ADAM Proteins | 1 | 2015 | 59 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2018 | 7086 | 0.030 |
Why?
| 3T3 Cells | 2 | 2006 | 153 | 0.030 |
Why?
| Fibroblasts | 2 | 2011 | 948 | 0.030 |
Why?
| Uncoupling Protein 1 | 1 | 2014 | 15 | 0.030 |
Why?
| Myosin Heavy Chains | 1 | 2015 | 170 | 0.030 |
Why?
| Weight Loss | 1 | 2020 | 734 | 0.030 |
Why?
| Cluster Analysis | 1 | 2015 | 482 | 0.030 |
Why?
| Ion Channels | 1 | 2014 | 133 | 0.030 |
Why?
| Time Factors | 1 | 2025 | 6556 | 0.030 |
Why?
| Antihypertensive Agents | 1 | 2018 | 485 | 0.030 |
Why?
| Mice, Knockout | 2 | 2013 | 2871 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 769 | 0.030 |
Why?
| Genome, Human | 1 | 2015 | 393 | 0.030 |
Why?
| Mast Cells | 1 | 2014 | 142 | 0.030 |
Why?
| Mitochondrial Proteins | 1 | 2014 | 248 | 0.020 |
Why?
| Hypertension | 1 | 2021 | 1242 | 0.020 |
Why?
| Demography | 1 | 2013 | 279 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2015 | 570 | 0.020 |
Why?
| Organ Specificity | 1 | 2012 | 296 | 0.020 |
Why?
| TWEAK Receptor | 1 | 2011 | 5 | 0.020 |
Why?
| United States | 2 | 2022 | 13903 | 0.020 |
Why?
| Tripartite Motif Proteins | 1 | 2011 | 29 | 0.020 |
Why?
| Up-Regulation | 1 | 2014 | 840 | 0.020 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 55 | 0.020 |
Why?
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2010 | 3 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2013 | 360 | 0.020 |
Why?
| Capillaries | 1 | 2011 | 103 | 0.020 |
Why?
| Atrophy | 1 | 2011 | 171 | 0.020 |
Why?
| Receptors, Adiponectin | 1 | 2010 | 19 | 0.020 |
Why?
| Rats | 1 | 2019 | 5500 | 0.020 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2011 | 153 | 0.020 |
Why?
| Protein Kinase C-alpha | 1 | 2010 | 37 | 0.020 |
Why?
| Muscle Proteins | 1 | 2011 | 220 | 0.020 |
Why?
| Stromal Cells | 1 | 2010 | 107 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 376 | 0.020 |
Why?
| Th1 Cells | 1 | 2010 | 138 | 0.020 |
Why?
| Collagen | 1 | 2011 | 434 | 0.020 |
Why?
| Oligonucleotides | 1 | 2010 | 140 | 0.020 |
Why?
| Energy Metabolism | 1 | 2014 | 874 | 0.020 |
Why?
| Waist-Hip Ratio | 1 | 2008 | 35 | 0.020 |
Why?
| Pilot Projects | 1 | 2014 | 1587 | 0.020 |
Why?
| Regulatory Factor X Transcription Factors | 1 | 2008 | 10 | 0.020 |
Why?
| X-Box Binding Protein 1 | 1 | 2008 | 9 | 0.020 |
Why?
| Mice, Obese | 1 | 2008 | 59 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 2008 | 39 | 0.020 |
Why?
| Activating Transcription Factor 6 | 1 | 2008 | 17 | 0.020 |
Why?
| eIF-2 Kinase | 1 | 2008 | 30 | 0.020 |
Why?
| Transcription Factor CHOP | 1 | 2008 | 30 | 0.020 |
Why?
| Patient Readmission | 1 | 2014 | 667 | 0.020 |
Why?
| Chelating Agents | 1 | 2008 | 68 | 0.020 |
Why?
| Sucrose | 1 | 2008 | 99 | 0.020 |
Why?
| Endoribonucleases | 1 | 2008 | 73 | 0.020 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 2007 | 6 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2010 | 672 | 0.020 |
Why?
| Heat-Shock Proteins | 1 | 2008 | 136 | 0.020 |
Why?
| Cell Fractionation | 1 | 2007 | 56 | 0.020 |
Why?
| Transcription Factor 7-Like 2 Protein | 1 | 2007 | 22 | 0.020 |
Why?
| Patient Discharge | 1 | 2014 | 857 | 0.020 |
Why?
| Glucose Transporter Type 4 | 1 | 2007 | 39 | 0.020 |
Why?
| Cell Communication | 1 | 2009 | 301 | 0.020 |
Why?
| Indians, North American | 1 | 2013 | 600 | 0.020 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2006 | 7 | 0.020 |
Why?
| Phosphatidate Phosphatase | 1 | 2006 | 5 | 0.020 |
Why?
| Blotting, Northern | 1 | 2006 | 200 | 0.020 |
Why?
| Signal Transduction | 2 | 2011 | 4925 | 0.020 |
Why?
| Molecular Chaperones | 1 | 2008 | 182 | 0.020 |
Why?
| Muscle Cells | 1 | 2006 | 42 | 0.020 |
Why?
| Protein Isoforms | 1 | 2008 | 391 | 0.020 |
Why?
| Isomerism | 1 | 2006 | 53 | 0.020 |
Why?
| Caspase 9 | 1 | 2006 | 56 | 0.020 |
Why?
| Diet, Carbohydrate-Restricted | 1 | 2006 | 32 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.020 |
Why?
| Phosphoproteins | 1 | 2008 | 332 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2006 | 5440 | 0.020 |
Why?
| Anilides | 1 | 2006 | 73 | 0.020 |
Why?
| DNA Primers | 1 | 2006 | 510 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2013 | 2717 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2007 | 345 | 0.020 |
Why?
| Caspase 3 | 1 | 2006 | 245 | 0.020 |
Why?
| Caspases | 1 | 2006 | 245 | 0.010 |
Why?
| Cell Count | 1 | 2005 | 314 | 0.010 |
Why?
| Genome | 1 | 2006 | 278 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2006 | 1085 | 0.010 |
Why?
| Life Style | 1 | 2006 | 460 | 0.010 |
Why?
| Colorado | 1 | 2014 | 4421 | 0.010 |
Why?
| Genes, Reporter | 1 | 2004 | 267 | 0.010 |
Why?
| RNA | 1 | 2010 | 883 | 0.010 |
Why?
| Homeostasis | 1 | 2007 | 611 | 0.010 |
Why?
| Stem Cells | 1 | 2007 | 577 | 0.010 |
Why?
| Enhancer Elements, Genetic | 1 | 2004 | 177 | 0.010 |
Why?
| Reactive Oxygen Species | 1 | 2006 | 596 | 0.010 |
Why?
| Base Sequence | 1 | 2006 | 2142 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2006 | 2058 | 0.010 |
Why?
| Peptide Fragments | 1 | 2006 | 692 | 0.010 |
Why?
| Antioxidants | 1 | 2006 | 559 | 0.010 |
Why?
| Genotype | 1 | 2007 | 1839 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2006 | 2832 | 0.010 |
Why?
| Calcium | 1 | 2008 | 1213 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2006 | 1698 | 0.010 |
Why?
| Myocardium | 1 | 2006 | 980 | 0.010 |
Why?
| Muscle, Smooth | 1 | 2002 | 157 | 0.010 |
Why?
| Morbidity | 1 | 2002 | 302 | 0.010 |
Why?
| DNA-Binding Proteins | 1 | 2008 | 1443 | 0.010 |
Why?
| Cardiovascular System | 1 | 2002 | 137 | 0.010 |
Why?
| Prospective Studies | 1 | 2012 | 7133 | 0.010 |
Why?
| Blood Coagulation | 1 | 2002 | 238 | 0.010 |
Why?
| Promoter Regions, Genetic | 1 | 2004 | 1207 | 0.010 |
Why?
| Mortality | 1 | 2002 | 307 | 0.010 |
Why?
| Mitochondria | 1 | 2006 | 877 | 0.010 |
Why?
|
|
Rasouli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|